{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:32:30Z","timestamp":1786116750526,"version":"build-2736575974"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Major depression (MD) treatments have limited efficacy and target few mechanisms, highlighting the need for innovative drug discovery. Drugs targeting genetically supported proteins are 2.6 times more likely to succeed in drug development. Here, we use genetic methods to identify and prioritise MD drug targets, leveraging genome-wide association study (GWAS) summary statistics from &gt;525,000 MD cases. We derived exposure data from 10 datasets measuring protein quantitative trait loci (pQTLs) and gene expression levels (eQTLs) in blood, cerebrospinal fluid, and brain tissues. We performed\n                    <jats:italic>cis<\/jats:italic>\n                    -Mendelian randomisation (MR) on 3469 druggable targets (genes encoding proteins targeted by existing compounds or experimentally predicted to be druggable). To strengthen causal inference, we implemented robust MR estimators, colocalisation, external replication, and assessed directional consistency across tissues. We integrated\n                    <jats:italic>cis<\/jats:italic>\n                    -MR effect directions with drug mechanisms and clinical annotations to infer potential therapeutic effects. Validation analyses showed that 82% of drugs approved for depression\/anxiety had \u22651 significant MR target, compared to 51% for compounds in clinical trials. For repurposing, we prioritised 54 targets of compounds developed for other conditions with estimated beneficial effects on MD (e.g., an inhibitor for a risk-increasing target). Ten high-priority targets of brain-penetrating compounds included ACE and NISCH (cardiovascular drugs), NDUFA2, NDUFB6, and NDUFS1 (metformin), CDK4, NTRK3, and MET (oncology inhibitors), and GLS and NOS2 (enzyme inhibitors). We found genetic evidence for established and novel MD targets across the drug development pipeline. Novel targets point to mechanisms beyond monoaminergic systems, most with approved drugs for other conditions, offering immediate repurposing opportunities.\n                  <\/jats:p>","DOI":"10.1038\/s41398-026-04137-9","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:15:57Z","timestamp":1780395357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An integrative mendelian randomisation and drug mechanism framework for target prioritisation and therapeutic repurposing in major depression"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7869-3754","authenticated-orcid":false,"given":"Abigail R.","family":"ter Kuile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3319-1937","authenticated-orcid":false,"given":"Chris","family":"Finan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5113-6870","authenticated-orcid":false,"given":"Sandesh","family":"Chopade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-1989","authenticated-orcid":false,"given":"Marion","family":"van Vugt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3505-3586","authenticated-orcid":false,"given":"Nikita","family":"Hukerikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1430-3614","authenticated-orcid":false,"given":"Serena","family":"Barral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-8377","authenticated-orcid":false,"given":"Argyris","family":"Stringaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1327-0424","authenticated-orcid":false,"given":"Amand F.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9726-603X","authenticated-orcid":false,"given":"Karoline","family":"Kuchenbaecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2557-4716","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Pingault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"4137_CR1","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","volume":"9","author":"GBD 2019 Mental Disorders Collaborators..","year":"2022","unstructured":"GBD 2019 Mental Disorders Collaborators.. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137\u201350.","journal-title":"Lancet Psychiatry"},{"key":"4137_CR2","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340.","journal-title":"Am J Psychiatry"},{"key":"4137_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/JCP.0b013e3182228619","volume":"31","author":"D Souery","year":"2011","unstructured":"Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31:512\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"4137_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","volume":"4","author":"CJ Harmer","year":"2017","unstructured":"Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. Lancet Psychiatry. 2017;4:409\u201318.","journal-title":"Lancet Psychiatry"},{"key":"4137_CR5","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15:e1008489.","journal-title":"PLoS Genet"},{"key":"4137_CR6","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3314","volume":"47","author":"MR Nelson","year":"2015","unstructured":"Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856\u201360.","journal-title":"Nat Genet"},{"key":"4137_CR7","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41586-024-07316-0","volume":"629","author":"EV Minikel","year":"2024","unstructured":"Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024;629:624\u20139.","journal-title":"Nature"},{"key":"4137_CR8","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/d41573-023-00158-x","volume":"22","author":"PV Rusina","year":"2023","unstructured":"Rusina PV, Falaguera MJ, Romero JMR, McDonagh EM, Dunham I, Ochoa D. Genetic support for FDA-approved drugs over the past decade. Nat Rev Drug Discov. 2023;22:864.","journal-title":"Nat Rev Drug Discov"},{"key":"4137_CR9","doi-asserted-by":"publisher","first-page":"eaag1166","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9:eaag1166.","journal-title":"Sci Transl Med"},{"key":"4137_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16969-0","volume":"11","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, Finan C, Gordillo-Mara\u00f1\u00f3n M, Asselbergs FW, Freitag DF, Patel RS, et al. Genetic drug target validation using mendelian randomisation. Nat Commun. 2020;11:3255.","journal-title":"Nat Commun"},{"key":"4137_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54849-w","volume":"9","author":"AD Hingorani","year":"2019","unstructured":"Hingorani AD, Kuan V, Finan C, Kruger FA, Gaulton A, Chopade S, et al. Improving the odds of drug development success through human genomics: modelling study. Sci Rep. 2019;9:18911.","journal-title":"Sci Rep"},{"key":"4137_CR12","volume":"1","author":"I Daghlas","year":"2023","unstructured":"Daghlas I, Gill D. Mendelian randomization as a tool to inform drug development using human genetics. Cambridge Prisms: Precision Medicine. 2023;1:e16.","journal-title":"Cambridge Prisms: Precision Medicine"},{"key":"4137_CR13","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/ije\/dyx207","volume":"46","author":"VM Walker","year":"2017","unstructured":"Walker VM, Davey Smith G, Davies NM, Martin RM. Mendelian randomization: a novel approach for the prediction of adverse drug events and drug repurposing opportunities. Int J Epidemiol. 2017;46:2078\u201389.","journal-title":"Int J Epidemiol"},{"key":"4137_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25731-z","volume":"12","author":"M Gordillo-Mara\u00f1\u00f3n","year":"2021","unstructured":"Gordillo-Mara\u00f1\u00f3n M, Zwierzyna M, Charoen P, Drenos F, Chopade S, Shah T, et al. Validation of lipid-related therapeutic targets for coronary heart disease prevention using human genetics. Nat Commun. 2021;12:6120.","journal-title":"Nat Commun"},{"key":"4137_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26280-1","volume":"12","author":"CS Storm","year":"2021","unstructured":"Storm CS, Kia DA, Almramhi MM, Bandres-Ciga S, Finan C, International Parkinson\u2019s Disease Genomics Consortium (IPDGC), et al. Finding genetically-supported drug targets for Parkinson\u2019s disease using Mendelian randomization of the druggable genome. Nat Commun. 2021;12:7342.","journal-title":"Nat Commun"},{"key":"4137_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.cell.2024.12.002","volume":"188","author":"Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Electronic address: andrew.mcintosh@ed.ac.uk, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium..","year":"2025","unstructured":"Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Electronic address: andrew.mcintosh@ed.ac.uk, Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium.. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell. 2025;188:640\u2013652.e9.","journal-title":"Cell"},{"key":"4137_CR17","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41386-022-01456-5","volume":"48","author":"J Liu","year":"2023","unstructured":"Liu J, Cheng Y, Li M, Zhang Z, Li T, Luo X-J. Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. Neuropsychopharmacology. 2023;48:270\u201380.","journal-title":"Neuropsychopharmacology"},{"key":"4137_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/s41562-024-02073-6","volume":"9","author":"Y Li","year":"2025","unstructured":"Li Y, Dang X, Chen R, Teng Z, Wang J, Li S, et al. Cross-ancestry genome-wide association study and systems-level integrative analyses implicate new risk genes and therapeutic targets for depression. Nat Hum Behav. 2025;9:806\u201323.","journal-title":"Nat Hum Behav"},{"key":"4137_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add4984","volume":"9","author":"AF Schmidt","year":"2023","unstructured":"Schmidt AF, Bourfiss M, Alasiri A, Puyol-Anton E, Chopade S, van Vugt M, et al. Druggable proteins influencing cardiac structure and function: implications for heart failure therapies and cancer cardiotoxicity. Sci Adv. 2023;9:eadd4984.","journal-title":"Sci Adv"},{"key":"4137_CR20","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-021-00978-w","volume":"53","author":"E Ferkingstad","year":"2021","unstructured":"Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrmisdottir EL, et al. Large-scale integration of the plasma proteome with genetics and disease. Nat Genet. 2021;53:1712\u201321.","journal-title":"Nat Genet"},{"key":"4137_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","volume":"622","author":"BB Sun","year":"2023","unstructured":"Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329\u201338.","journal-title":"Nature"},{"key":"4137_CR22","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","volume":"53","author":"U V\u00f5sa","year":"2021","unstructured":"V\u00f5sa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53:1300\u201310.","journal-title":"Nat Genet"},{"key":"4137_CR23","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/s41593-021-00886-6","volume":"24","author":"C Yang","year":"2021","unstructured":"Yang C, Farias FHG, Ibanez L, Suhy A, Sadler B, Fernandez MV, et al. Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nat Neurosci. 2021;24:1302\u201312.","journal-title":"Nat Neurosci"},{"key":"4137_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ajhg.2021.01.012","volume":"108","author":"C Robins","year":"2021","unstructured":"Robins C, Liu Y, Fan W, Duong DM, Meigs J, Harerimana NV, et al. Genetic control of the human brain proteome. Am J Hum Genet. 2021;108:400\u201310.","journal-title":"Am J Hum Genet"},{"key":"4137_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41588-023-01300-6","volume":"55","author":"N de Klein","year":"2023","unstructured":"de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen C-Y, et al. Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases. Nat Genet. 2023;55:377\u201388.","journal-title":"Nat Genet"},{"key":"4137_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-06563-x","volume":"622","author":"GH Eldjarn","year":"2023","unstructured":"Eldjarn GH, Ferkingstad E, Lund SH, Helgason H, Magnusson OT, Gunnarsdottir K, et al. Large-scale plasma proteomics comparisons through genetics and disease associations. Nature. 2023;622:348\u201358.","journal-title":"Nature"},{"key":"4137_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1039\/C7MD00633K","volume":"9","author":"KK Brown","year":"2018","unstructured":"Brown KK, Hann MM, Lakdawala AS, Santos R, Thomas PJ, Todd K. Approaches to target tractability assessment - a practical perspective. Medchemcomm. 2018;9:606\u201313.","journal-title":"Medchemcomm"},{"key":"4137_CR28","doi-asserted-by":"publisher","first-page":"D930","DOI":"10.1093\/nar\/gky1075","volume":"47","author":"D Mendez","year":"2019","unstructured":"Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, F\u00e9lix E, et al. ChEMBL: towards direct deposition of bioassay data. Nucleic Acids Res. 2019;47:D930\u201340.","journal-title":"Nucleic Acids Res"},{"key":"4137_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.117462","volume":"390","author":"N Hukerikar","year":"2024","unstructured":"Hukerikar N, Hingorani AD, Asselbergs FW, Finan C, Schmidt AF. Prioritising genetic findings for drug target identification and validation. Atherosclerosis. 2024;390:117462.","journal-title":"Atherosclerosis"},{"key":"4137_CR30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/ije\/dyy258","volume":"48","author":"J Bowden","year":"2019","unstructured":"Bowden J, Del Greco M F, Minelli C, Zhao Q, Lawlor DA, Sheehan NA, et al. Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. Int J Epidemiol. 2019;48:728\u201342.","journal-title":"Int J Epidemiol"},{"key":"4137_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2307\/2171753","volume":"65","author":"D Staiger","year":"1997","unstructured":"Staiger D, Stock JH. Instrumental variables regression with weak instruments. Econometrica. 1997;65:557.","journal-title":"Econometrica"},{"key":"4137_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource with deep phenotyping and genomic data. Nature. 2018;562:203\u20139.","journal-title":"Nature"},{"key":"4137_CR33","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/sim.7221","volume":"36","author":"J Bowden","year":"2017","unstructured":"Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data mendelian randomization. Stat Med. 2017;36:1783\u2013802.","journal-title":"Stat Med"},{"key":"4137_CR34","doi-asserted-by":"publisher","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13:e1007081.","journal-title":"PLoS Genet"},{"key":"4137_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00439-003-1075-5","volume":"114","author":"A Stenzel","year":"2004","unstructured":"Stenzel A, Lu T, Koch WA, Hampe J, Guenther SM, De La Vega FM, et al. Patterns of linkage disequilibrium in the MHC region on human chromosome 6p. Hum Genet. 2004;114:377\u201385.","journal-title":"Hum Genet"},{"key":"4137_CR36","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1002\/gepi.22077","volume":"41","author":"S Burgess","year":"2017","unstructured":"Burgess S, Zuber V, Valdes-Marquez E, Sun BB, Hopewell JC. Mendelian randomization with fine-mapped genetic data: choosing from large numbers of correlated instrumental variables. Genet Epidemiol. 2017;41:714\u201325.","journal-title":"Genet Epidemiol"},{"key":"4137_CR37","doi-asserted-by":"publisher","first-page":"186","DOI":"10.12688\/wellcomeopenres.15555.1","volume":"4","author":"S Burgess","year":"2019","unstructured":"Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing mendelian randomization investigations. Wellcome Open Res. 2019;4:186.","journal-title":"Wellcome Open Res"},{"key":"4137_CR38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.12688\/wellcomeopenres.19995.2","volume":"8","author":"A Patel","year":"2023","unstructured":"Patel A, Ye T, Xue H, Lin Z, Xu S, Woolf B, et al. MendelianRandomization v0.9.0: updates to an R package for performing mendelian randomization analyses using summarized data. Wellcome Open Res. 2023;8:449.","journal-title":"Wellcome Open Res"},{"key":"4137_CR39","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/gepi.22295","volume":"44","author":"EAW Slob","year":"2020","unstructured":"Slob EAW, Burgess S. A comparison of robust mendelian randomization methods using summary data. Genet Epidemiol. 2020;44:313\u201329.","journal-title":"Genet Epidemiol"},{"key":"4137_CR40","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44:512\u201325.","journal-title":"Int J Epidemiol"},{"key":"4137_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14156-4","volume":"11","author":"S Burgess","year":"2020","unstructured":"Burgess S, Foley CN, Allara E, Staley JR, Howson JMM. A robust and efficient method for mendelian randomization with hundreds of genetic variants. Nat Commun. 2020;11:376.","journal-title":"Nat Commun"},{"key":"4137_CR42","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40:304\u201314.","journal-title":"Genet Epidemiol"},{"key":"4137_CR43","doi-asserted-by":"publisher","first-page":"e1008720","DOI":"10.1371\/journal.pgen.1008720","volume":"16","author":"C Wallace","year":"2020","unstructured":"Wallace C. Eliciting priors and relaxing the single causal variant assumption in colocalisation analyses. PLoS Genet. 2020;16:e1008720.","journal-title":"PLoS Genet"},{"key":"4137_CR44","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.ajhg.2022.04.001","volume":"109","author":"V Zuber","year":"2022","unstructured":"Zuber V, Grinberg NF, Gill D, Manipur I, Slob EAW, Patel A, et al. Combining evidence from mendelian randomization and colocalization: review and comparison of approaches. Am J Hum Genet. 2022;109:767\u201382.","journal-title":"Am J Hum Genet"},{"key":"4137_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41588-025-02485-8","volume":"58","author":"NI Strom","year":"2026","unstructured":"Strom NI, Verhulst B, Bacanu S-A, Cheesman R, Purves KL, Gedik H, et al. Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling. Nat Genet. 2026;58:275\u201388.","journal-title":"Nat Genet"},{"key":"4137_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1017\/S2045796015000189","volume":"24","author":"RC Kessler","year":"2015","unstructured":"Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al. Anxious and non-anxious major depressive disorder in the world health organization world mental health surveys. Epidemiol Psychiatr Sci. 2015;24:210\u201326.","journal-title":"Epidemiol Psychiatr Sci"},{"key":"4137_CR47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5498\/wjp.v5.i4.366","volume":"5","author":"JD Coplan","year":"2015","unstructured":"Coplan JD, Aaronson CJ, Panthangi V, Kim Y. Treating comorbid anxiety and depression: psychosocial and pharmacological approaches. World J Psychiatry. 2015;5:366\u201378.","journal-title":"World J Psychiatry"},{"key":"4137_CR48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb6242","volume":"6","author":"\u00c1 Duffy","year":"2020","unstructured":"Duffy \u00c1, Verbanck M, Dobbyn A, Won H-H, Rein JL, Forrest IS, et al. Tissue-specific genetic features inform prediction of drug side effects in clinical trials. Sci Adv. 2020;6:eabb6242.","journal-title":"Sci Adv"},{"key":"4137_CR49","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51:D638\u201346.","journal-title":"Nucleic Acids Res"},{"key":"4137_CR50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41392-024-01738-y","volume":"9","author":"L Cui","year":"2024","unstructured":"Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, et al. Major depressive disorder: hypothesis, mechanism, prevention and treatment. Signal Transduct Target Ther. 2024;9:30.","journal-title":"Signal Transduct Target Ther"},{"key":"4137_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.947785","volume":"13","author":"F Zhao","year":"2022","unstructured":"Zhao F, Cheng Z, Piao J, Cui R, Li B. Dopamine receptors: is it possible to become a therapeutic target for depression?. Front Pharmacol. 2022;13:947785.","journal-title":"Front Pharmacol"},{"key":"4137_CR52","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrn3504","volume":"14","author":"P Paoletti","year":"2013","unstructured":"Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013;14:383\u2013400.","journal-title":"Nat Rev Neurosci"},{"key":"4137_CR53","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3390\/ph17050639","volume":"17","author":"AO Egunlusi","year":"2024","unstructured":"Egunlusi AO, Joubert J. NMDA receptor antagonists: emerging insights into molecular mechanisms and clinical applications in neurological disorders. Pharmaceuticals (Basel). 2024;17:639.","journal-title":"Pharmaceuticals (Basel)"},{"key":"4137_CR54","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.3390\/biom12121784","volume":"12","author":"MP Goldschen-Ohm","year":"2022","unstructured":"Goldschen-Ohm MP. Benzodiazepine modulation of GABAA receptors: a mechanistic perspective. Biomolecules. 2022;12:1784.","journal-title":"Biomolecules"},{"key":"4137_CR55","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1055\/a-2291-7204","volume":"57","author":"TA Merza Mohammad","year":"2024","unstructured":"Merza Mohammad TA, Merza Mohammad TA, Salman DM, Jaafar HM. Pentoxifylline as a novel add-on therapy for major depressive disorder in adult patients: a randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2024;57:205\u201314.","journal-title":"Pharmacopsychiatry"},{"key":"4137_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2021.110635","volume":"150","author":"S-O Yasrebi","year":"2021","unstructured":"Yasrebi S-O, Momtazmanesh S, Moghaddam HS, Shahmansouri N, Mehrpooya M, Arbabi M, et al. Pentoxifylline for treatment of major depression after percutaneous coronary intervention or coronary artery bypass grafting: a randomized, double-blind, placebo-controlled trial. J Psychosom Res. 2021;150:110635.","journal-title":"J Psychosom Res"},{"key":"4137_CR57","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/YIC.0000000000000353","volume":"36","author":"M Farajollahi-Moghadam","year":"2021","unstructured":"Farajollahi-Moghadam M, Sanjari-Moghaddam H, Ghazizadeh Hasemi M, Sanatian Z, Talaei A, Akhondzadeh S. Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial: a randomized, double-blind, placebo-controlled clinical trial. Int Clin Psychopharmacol. 2021;36:140\u20136.","journal-title":"Int Clin Psychopharmacol"},{"key":"4137_CR58","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1159\/000492619","volume":"87","author":"SM El-Haggar","year":"2018","unstructured":"El-Haggar SM, Eissa MA, Mostafa TM, El-Attar KS, Abdallah MS. The phosphodiesterase inhibitor pentoxifylline as a novel adjunct to antidepressants in major depressive disorder patients: a proof-of-concept, randomized, double-blind, placebo-controlled trial. Psychother Psychosom. 2018;87:331\u20139.","journal-title":"Psychother Psychosom"},{"key":"4137_CR59","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","volume":"13","author":"DH Maurice","year":"2014","unstructured":"Maurice DH, Ke H, Ahmad F, Wang Y, Chung J, Manganiello VC. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014;13:290\u2013314.","journal-title":"Nat Rev Drug Discov"},{"key":"4137_CR60","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s10787-024-01616-7","volume":"33","author":"A Ramzi","year":"2025","unstructured":"Ramzi A, Maya S, Balousha N, Amin M, Powell RC, Shiha MR. Effects of the anti-inflammatory pentoxifylline on psychiatric and neuropsychiatric conditions: exploring various off-label utilities with meta-analyses. Inflammopharmacology. 2025;33:105\u201319.","journal-title":"Inflammopharmacology"},{"key":"4137_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1177\/0004867417721654","volume":"52","author":"DJ Brownstein","year":"2018","unstructured":"Brownstein DJ, Salagre E, K\u00f6hler C. Blockade of the angio-tensin system improves mental health domain of quality of life: ameta-analysis of randomized clinical trials. Aust N Z J Psychiatry. 2018;52:24\u201338.","journal-title":"Aust N Z J Psychiatry"},{"key":"4137_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0916-3","volume":"15","author":"J Vian","year":"2017","unstructured":"Vian J, Pereira C, Chavarria V, K\u00f6hler C, Stubbs B, Quevedo J, et al. The renin-angiotensin system: a possible new target for depression. BMC Med. 2017;15:144.","journal-title":"BMC Med"},{"key":"4137_CR63","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14525","volume":"30","author":"NH Ali","year":"2024","unstructured":"Ali NH, Al-Kuraishy HM, Al-Gareeb AI, Albuhadily AK, Hamad RS, Alexiou A, et al. Role of brain renin-angiotensin system in depression: a new perspective. CNS Neurosci Ther. 2024;30:e14525.","journal-title":"CNS Neurosci Ther"},{"key":"4137_CR64","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41588-023-01596-4","volume":"56","author":"X Meng","year":"2024","unstructured":"Meng X, Navoly G, Giannakopoulou O, Levey DF, Koller D, Pathak GA, et al. Multi-ancestry genome-wide association study of major depression aids locus discovery, fine mapping, gene prioritization and causal inference. Nat Genet. 2024;56:222\u201333.","journal-title":"Nat Genet"},{"key":"4137_CR65","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1523\/JNEUROSCI.2904-18.2019","volume":"39","author":"J Zemdegs","year":"2019","unstructured":"Zemdegs J, Martin H, Pintana H, Bullich S, Manta S, Marqu\u00e9s MA, et al. Metformin promotes anxiolytic and antidepressant-like responses in insulin-resistant mice by decreasing circulating branched-chain amino acids. J Neurosci. 2019;39:5935\u201348.","journal-title":"J Neurosci"},{"key":"4137_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108415","volume":"102","author":"IP Mendon\u00e7a","year":"2022","unstructured":"Mendon\u00e7a IP, Paiva IHRde, Duarte-Silva EP, Melo MGde, Silva RSda, Oliveira WHde, et al. Metformin and fluoxetine improve depressive-like behavior in a murine model of Parkinso\u0144s disease through the modulation of neuroinflammation, neurogenesis and neuroplasticity. Int Immunopharmacol. 2022;102:108415.","journal-title":"Int Immunopharmacol"},{"key":"4137_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2023.103894","volume":"92","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chan VK-Y, Chan SSM, Chan EWY, Lee CH, Wong IC, et al. Effect of metformin on the risk of depression: a systematic review and meta-regression of observational studies. Asian J Psychiatr. 2024;92:103894.","journal-title":"Asian J Psychiatr"},{"key":"4137_CR68","doi-asserted-by":"publisher","first-page":"21m14022","DOI":"10.4088\/JCP.21m14022","volume":"83","author":"CV Calkin","year":"2022","unstructured":"Calkin CV, Chengappa KNR, Cairns K, Cookey J, Gannon J, Alda M, et al. Treating insulin resistance with metformin as a strategy to improve clinical outcomes in treatment-resistant bipolar depression (the TRIO-BD study): a randomized, quadruple-masked, placebo-controlled clinical trial: a randomized, quadruple-masked, placebo-controlled clinical trial. J Clin Psychiatry. 2022;83:21m14022.","journal-title":"J Clin Psychiatry"},{"key":"4137_CR69","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2016.10.007","volume":"208","author":"B Keller","year":"2017","unstructured":"Keller B, Garc\u00eda-Sevilla JA. Dysregulation of IRAS\/nischarin and other potential I1-imidazoline receptors in major depression postmortem brain: downregulation of basal contents by antidepressant drug treatments. J Affect Disord. 2017;208:646\u201352.","journal-title":"J Affect Disord"},{"key":"4137_CR70","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.neuint.2008.09.001","volume":"53","author":"M-Y Zhu","year":"2008","unstructured":"Zhu M-Y, Wang W-P, Huang J, Feng Y-Z, Regunathan S, Bissette G. Repeated immobilization stress alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. Neurochem Int. 2008;53:346\u201354.","journal-title":"Neurochem Int"},{"key":"4137_CR71","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/j.1460-9568.2008.06104.x","volume":"27","author":"M-Y Zhu","year":"2008","unstructured":"Zhu M-Y, Wang W-P, Cai Z-W, Regunathan S, Ordway G. Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain. Eur J Neurosci. 2008;27:1320\u201332.","journal-title":"Eur J Neurosci"},{"key":"4137_CR72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.brainres.2017.03.004","volume":"1663","author":"NB Gawali","year":"2017","unstructured":"Gawali NB, Bulani VD, Gursahani MS, Deshpande PS, Kothavade PS, Juvekar AR. Agmatine attenuates chronic unpredictable mild stress-induced anxiety, depression-like behaviours and cognitive impairment by modulating nitrergic signalling pathway. Brain Res. 2017;1663:66\u201377.","journal-title":"Brain Res"},{"key":"4137_CR73","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.neuropharm.2009.06.035","volume":"57","author":"BG Taksande","year":"2009","unstructured":"Taksande BG, Kotagale NR, Tripathi SJ, Ugale RR, Chopde CT. Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology. 2009;57:415\u201324.","journal-title":"Neuropharmacology"},{"key":"4137_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173739","volume":"892","author":"S Rahangdale","year":"2021","unstructured":"Rahangdale S, Fating R, Gajbhiye M, Kapse M, Inamdar N, Kotagale N, et al. Involvement of agmatine in antidepressant-like effect of HMG-CoA reductase inhibitors in mice. Eur J Pharmacol. 2021;892:173739.","journal-title":"Eur J Pharmacol"},{"key":"4137_CR75","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1084\/jem.20102167","volume":"208","author":"B Artegiani","year":"2011","unstructured":"Artegiani B, Lindemann D, Calegari F. Overexpression of cdk4 and cyclinD1 triggers greater expansion of neural stem cells in the adult mouse brain. J Exp Med. 2011;208:937\u201348.","journal-title":"J Exp Med"},{"key":"4137_CR76","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00018-023-04920-7","volume":"80","author":"N Pedraza","year":"2023","unstructured":"Pedraza N, Monserrat MV, Ferrezuelo F, Torres-Rosell J, Colomina N, Miguez-Cabello F, et al. Cyclin D1-Cdk4 regulates neuronal activity through phosphorylation of GABAA receptors. Cell Mol Life Sci. 2023;80:280.","journal-title":"Cell Mol Life Sci"},{"key":"4137_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-213X-7-57","volume":"7","author":"C Li","year":"2007","unstructured":"Li C, Li X, Chen W, Yu S, Chen J, Wang H, et al. The different roles of cyclinD1-CDK4 in STP and mGluR-LTD during the postnatal development in mice hippocampus area CA1. BMC Dev Biol. 2007;7:57.","journal-title":"BMC Dev Biol"},{"key":"4137_CR78","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/14728222.2020.1846720","volume":"24","author":"AS de Miranda","year":"2020","unstructured":"de Miranda AS, de Barros JLVM, Teixeira AL. Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety?. Expert Opin Ther Targets. 2020;24:1225\u201338.","journal-title":"Expert Opin Ther Targets"},{"key":"4137_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.683609","volume":"9","author":"C Desole","year":"2021","unstructured":"Desole C, Gallo S, Vitacolonna A, Montarolo F, Bertolotto A, Vivien D, et al. HGF and MET: From brain development to neurological disorders. Front Cell Dev Biol. 2021;9:683609.","journal-title":"Front Cell Dev Biol"},{"key":"4137_CR80","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11523-021-00865-8","volume":"17","author":"M Sisi","year":"2022","unstructured":"Sisi M, Fusaroli M, De Giglio A, Facchinetti F, Ardizzoni A, Raschi E, et al. Psychiatric adverse reactions to anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer: analysis of spontaneous reports submitted to the FDA adverse event reporting system. Target Oncol. 2022;17:43\u201351.","journal-title":"Target Oncol"},{"key":"4137_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1268672","volume":"13","author":"MA Barbieri","year":"2023","unstructured":"Barbieri MA, Russo G, Sorbara EE, Cicala G, Franchina T, Santarpia M, et al. Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA adverse event reporting system. Front Oncol. 2023;13:1268672.","journal-title":"Front Oncol"},{"key":"4137_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14862","volume":"30","author":"Z Xiao","year":"2024","unstructured":"Xiao Z, Cao J, Wu S, Zhou T, Li C, Duan J, et al. Spectrum of psychiatric adverse reactions to cyclin-dependent kinases 4\/6 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system. CNS Neurosci Ther. 2024;30:e14862.","journal-title":"CNS Neurosci Ther"},{"key":"4137_CR83","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41386-018-0177-7","volume":"44","author":"X Zhu","year":"2019","unstructured":"Zhu X, Nedelcovych MT, Thomas AG, Hasegawa Y, Moreno-Megui A, Coomer W, et al. JHU-083 selectively blocks glutaminase activity in brain CD11b+ cells and prevents depression-associated behaviors induced by chronic social defeat stress. Neuropsychopharmacology. 2019;44:683\u201394.","journal-title":"Neuropsychopharmacology"},{"key":"4137_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbih.2022.100478","volume":"23","author":"BJ Bell","year":"2022","unstructured":"Bell BJ, Hollinger KR, Deme P, Sakamoto S, Hasegawa Y, Volsky D, et al. Glutamine antagonist JHU083 improves psychosocial behavior and sleep deficits in EcoHIV-infected mice. Brain Behav Immun Health. 2022;23:100478.","journal-title":"Brain Behav Immun Health"},{"key":"4137_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00759","volume":"22","author":"M Huang","year":"2025","unstructured":"Huang M, Li Y, Thomas AG, Sharma A, Liyanage W, Tich\u00fd T, et al. Inhibition of microglial glutaminase alleviates chronic stress-induced neurobehavioral and cognitive deficits. Neurotherapeutics. 2025;22:e00759.","journal-title":"Neurotherapeutics"},{"key":"4137_CR86","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1177\/1535370221997052","volume":"246","author":"PM Liy","year":"2021","unstructured":"Liy PM, Puzi NNA, Jose S, Vidyadaran S. Nitric oxide modulation in neuroinflammation and the role of mesenchymal stem cells. Exp Biol Med (Maywood). 2021;246:2399\u2013406.","journal-title":"Exp Biol Med (Maywood)"},{"key":"4137_CR87","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","volume":"33","author":"U F\u00f6rstermann","year":"2012","unstructured":"F\u00f6rstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829\u201337.","journal-title":"Eur Heart J"},{"key":"4137_CR88","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.neuropharm.2011.09.004","volume":"62","author":"K Montezuma","year":"2012","unstructured":"Montezuma K, Biojone C, Lisboa SF, Cunha FQ, Guimar\u00e3es FS, Joca SRL. Inhibition of iNOS induces antidepressant-like effects in mice: pharmacological and genetic evidence. Neuropharmacology. 2012;62:485\u201391.","journal-title":"Neuropharmacology"},{"key":"4137_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2020.112720","volume":"392","author":"F Beheshti","year":"2020","unstructured":"Beheshti F, Hashemzehi M, Hosseini M, Marefati N, Memarpour S. Inducible nitric oxide synthase plays a role in depression- and anxiety-like behaviors chronically induced by lipopolysaccharide in rats: Evidence from inflammation and oxidative stress. Behav Brain Res. 2020;392:112720.","journal-title":"Behav Brain Res"},{"key":"4137_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.923177","volume":"13","author":"AA Coelho","year":"2022","unstructured":"Coelho AA, Vila-Verde C, Sartim AG, Uliana DL, Braga LA, Guimar\u00e3es FS, et al. Inducible nitric oxide synthase inhibition in the medial prefrontal cortex attenuates the anxiogenic-like effect of acute restraint stress via CB1 receptors. Front Psychiatry. 2022;13:923177.","journal-title":"Front Psychiatry"},{"key":"4137_CR91","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn3138","volume":"13","author":"M Popoli","year":"2011","unstructured":"Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2011;13:22\u201337.","journal-title":"Nat Rev Neurosci"},{"key":"4137_CR92","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fnins.2015.00003","volume":"9","author":"H-JC Chen","year":"2015","unstructured":"Chen H-JC, Spiers JG, Sernia C, Lavidis NA. Response of the nitrergic system to activation of the neuroendocrine stress axis. Front Neurosci. 2015;9:3.","journal-title":"Front Neurosci"},{"key":"4137_CR93","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","volume":"6","author":"D Gill","year":"2021","unstructured":"Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 2021;6:16.","journal-title":"Wellcome Open Res"},{"key":"4137_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-025-01075-4","volume":"20","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Yu L, Bi C, Huang L, Su B, Nie J, et al. A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. Chin Med. 2025;20:40.","journal-title":"Chin Med"},{"key":"4137_CR95","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd2683","volume":"8","author":"J Jia","year":"2009","unstructured":"Jia J, Zhu F, Ma X, Cao Z, Cao ZW, Li Y, et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8:111\u201328.","journal-title":"Nat Rev Drug Discov"},{"key":"4137_CR96","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajhg.2022.12.017","volume":"110","author":"S Burgess","year":"2023","unstructured":"Burgess S, Mason AM, Grant AJ, Slob EAW, Gkatzionis A, Zuber V, et al. Using genetic association data to guide drug discovery and development: Review of methods and applications. Am J Hum Genet. 2023;110:195\u2013214.","journal-title":"Am J Hum Genet"},{"key":"4137_CR97","doi-asserted-by":"publisher","first-page":"100195.","DOI":"10.1016\/j.xgen.2022.100195","volume":"2","author":"H Zhao","year":"2022","unstructured":"Zhao H, Rasheed H, N\u00f8st TH, Cho Y, Liu Y, Bhatta L, et al. Proteome-wide mendelian randomization in global biobank meta-analysis reveals multi-ancestry drug targets for common diseases. Cell Genom. 2022;2:100195.","journal-title":"Cell Genom"},{"key":"4137_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.xgen.2023.100341","volume":"3","author":"MC Sadler","year":"2023","unstructured":"Sadler MC, Auwerx C, Deelen P, Kutalik Z. Multi-layered genetic approaches to identify approved drug targets. Cell Genom. 2023;3:100341.","journal-title":"Cell Genom"},{"key":"4137_CR99","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00213-017-4556-2","volume":"234","author":"SR Spierling","year":"2017","unstructured":"Spierling SR, Zorrilla EP. Don\u2019t stress about CRF: assessing the translational failures of CRF1antagonists. Psychopharmacology (Berl). 2017;234:1467\u201381.","journal-title":"Psychopharmacology (Berl)"},{"key":"4137_CR100","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1176\/appi.ajp.20250289","volume":"182","author":"AH Miller","year":"2025","unstructured":"Miller AH. Advancing an inflammatory subtype of major depression. Am J Psychiatry. 2025;182:516\u201324.","journal-title":"Am J Psychiatry"},{"key":"4137_CR101","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fncel.2019.00290","volume":"13","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Peng T, Gaur U, Silva M, Little P, Chen Z, et al. Role of corticotropin releasing factor in the neuroimmune mechanisms of depression: examination of current pharmaceutical and herbal therapies. Front Cell Neurosci. 2019;13:290.","journal-title":"Front Cell Neurosci"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04137-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04137-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04137-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T12:04:45Z","timestamp":1786017885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04137-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4137"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04137-9","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"392"}}